Loading patent…
AssigneesShimadzu Corporation, St. Luke's International University
InventorsYutaka AOKI, Makoto WATANABE, Taka-Aki SATO, Takeshi KIMURA, Takuya KOSHIZAKA, Jyunya OHTAKE, Yasuhisa KUMAKURA
Estimating the term…
To provide a highly reliable method for evaluating an onset risk of NAFLD and a biomarker for use in the method. A method for evaluating an onset risk of nonalcoholic fatty liver disease includes: an acquisition step of acquiring a sample derived from a body fluid of a subject; a detection step of detecting 14 kinds of compounds consisting of lactic acid, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, and tryptophan in the sample; and a use step of using all detection amounts of the 14 kinds of compounds obtained in the detection step.
A method for evaluating an onset risk of nonalcoholic fatty liver disease, the method comprising:
A biomarker for evaluating an onset risk of nonalcoholic fatty liver disease, the biomarker comprising 14 kinds of compounds consisting of lactic acid, alanine, acetylglycine, isoleucine, proline, serine, glutaric acid, α-ketoglutaric acid, creatinine, glutamic acid, asparagine, fructose, uric acid, and tryptophan.
Dependencies are inferred from the claim text.